戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  because it is not available on the hospital formulary).
2 administers its own benefit using a national formulary.
3  resource-poor world who work with a limited formulary.
4 in control over cancer drugs is the hospital formulary.
5 ric cyclosporine formulation on our hospital formulary.
6 increased in provinces with the most lenient formularies.
7 bia and Alberta, which have more restrictive formularies.
8 hat all of these medications are included in formularies.
9                               A total of 561 formularies (301 [53.7%] ACA; 260 [46.3%] Medicaid) were
10  was that the product was not covered by the formulary (49 690 rejected claims [29.2%]).
11 rage for one such agent include all on their formularies (a revised version would preclude a trial of
12  in the literature, the Ontario Drug Benefit Formulary, a recent Cochrane review on the use of TCSs i
13                           Considerations for formulary addition and its place in therapy are also dis
14                         Different changes in formulary administration may have dramatically different
15 red health plans that implemented changes in formulary administration with those in comparison groups
16                                      Limited formularies and adherence constraints in children jeopar
17 siderations and recommendations for hospital formularies and antibiotic stewardship programs regardin
18                ULT dosage is also limited by formularies and clinical inertia.
19                                     Personal formularies and core medication lists enable comparisons
20  guide countries in the creation of national formularies and policies for access, quality, and use of
21 evaluates the association between waste-free formularies and prescription drug spending for 2 large s
22 opayment required for all drugs) to a 3-tier formulary and implemented an across-the-board copayment
23 sly switched from a one-tier to a three-tier formulary and increased all enrollee copayments for medi
24 l study used Medicare Prescription Drug Plan Formulary and Pricing Information Files from quarter 3 o
25 were obtained from the Ontario Drug Benefits Formulary and the Ontario Case Costing Initiative.
26 nd administrators who want to make coverage, formulary, and purchasing decisions; and policymakers wh
27 cent Cochrane review largely based on the UK formulary, and the 4-category ATC classification.
28 priateness of therapy guidelines, antibiotic formulary, antibiotic stewardship programmes, public hea
29 lar benefits and adverse effects, a "stepped formulary" approach requiring an initial trial of one of
30 ing widely covered to include 95% or more of formularies at co-payments of $15 or less still resulted
31  covered (defined as inclusion in >or=90% of formularies at co-payments of <or=$35 without prior auth
32 ase of administration, famotidine because of formulary availability, sucralfate for a better side eff
33 generic drugs are offered on Medicare Part D formularies because they may not provide savings to plan
34  maintain intravenous quinidine gluconate on formulary because it is the only drug available to treat
35 cribe dermatologic medications; as insurance formularies become increasingly restrictive and more pat
36 haviours in accordance with British National Formulary (BNF) categories (known as chapters) showed th
37                                              Formulary breadth was low coverage if the 4-quarter movi
38                                       Narrow formularies can be used to increase rebates and manage t
39 d a combination inhaler before and after the formulary change were included in both the SCCS and coho
40                            Following the VHA formulary change, 260 268 patients switched from budeson
41 isciplinary learning to share strategies for formulary changes, electronic health record tools, and p
42 ond switched from a two-tier to a three-tier formulary, changing only the copayments for tier-3 drugs
43 nsing PrEP claims across key demographic and formulary characteristics.
44 adverse events, recommended indications, and formulary considerations.
45 lows: (1) selection of insurance plans whose formularies cover their medications in a low tier (eg, "
46                                              Formulary coverage and restrictions should be tailored f
47           In multivariable analyses, broader formulary coverage during baseline was associated with l
48                                              Formulary coverage evaluated by claim rejection reasons,
49 th MI to full prescription coverage or usual formulary coverage for all statins, beta-blockers, angio
50                         Beneficiary-weighted formulary coverage of brand-name and authorized generic
51  this cohort study of Medicare data, broader formulary coverage was associated with an 8% to 12% lowe
52 o examine 72 California and 43 Hawaii Part D formularies' coverage of 8 treatment classes (angiotensi
53 021 Medicare Advantage/Part D enrollment and formulary data.
54                   Calendar periods reflected formulary decision-making.
55                                     Personal formularies-defined as the number and mix of unique, new
56                  Little variation existed in formulary design across plans and products.
57  uses Medicare Part D prescription drug plan formulary files to characterize changes in coverage of b
58 009 and 2019 Medicare prescription drug plan formulary files to estimate annual out-of-pocket costs a
59 packages with different prices and different formularies for beneficiaries to choose from.
60 tridioides difficile treatments, were in the formulary for 100% (42314676 of 42314676) and 84.1% (355
61 ability in restrictiveness of the provincial formularies, illustrating the potential of a policy resp
62 d data were derived from the 2020-2021 IQVIA Formulary Impact Analyzer (a pharmacy transactions datab
63 ross-sectional analysis, data from the IQVIA Formulary Impact Analyzer (representing 63% of US prescr
64 e of anonymized pharmacy claims from IQVIA's Formulary Impact Analyzer, which captures more than 60%
65 to September 30, 2019, obtained from IQVIA's Formulary Impact Analyzer.
66 e copayment increases associated with 3-tier formulary implementation by 1 employer resulted in lower
67                                     A 3-tier formulary implementation resulted in a 17% decrease in t
68 iption drug formularies, which represent all formularies in 2014.
69 ample of all available Medicaid and ACA drug formularies in 2024 linked to the US Food and Drug Admin
70 ployers and health plans have adopted 3-tier formularies in an attempt to control costs for these and
71 nd health plans have adopted incentive-based formularies in an attempt to control prescription-drug c
72                  To determine whether Part D formularies in California (the state with the most Medic
73 value essential cancer medicines on national formularies in the context of supporting sustainable hea
74   As new long-acting treatments enter global formularies, interventions showing success with oral ART
75 ices, total PGA prescribing volume, and plan formularies involved.
76 ortantly, to avoid drug toxicities, a larger formulary is needed in resource-poor settings, and this
77 n features studied, including preferred drug/formulary lists, prior authorization, medication dosing/
78                                     Personal formularies, measured at the level of individual physici
79 on claims datasets, and Ontario Drug Benefit Formulary medication consumption costs.
80 estrictiveness of ezetimibe in public-funded formularies (most to least strict: British Columbia, Alb
81 insulin may not even be included on national formularies of essential drugs.
82 gard to whether drugs are listed on the drug formulary of a country or province.
83                          A sufficiently wide formulary of drugs should be developed for those with co
84 was posted in operating rooms and the online formulary, only recommended antibiotics were available i
85 he Medicare July 2014 Prescription Drug Plan Formulary, Pharmacy Network, and Pricing Information Fil
86 rices by offering the drug company favorable formulary placement and fewer utilization controls.
87                                The effect of formulary policy on the use of ezetimibe over time is un
88              Replacing current Part D median formulary prices with MCCPDC pricing could yield signifi
89 re Part D Spending dashboard, Q3-2022 Part D formulary prices, and Q3-2022 MCCPDC prices for seven se
90  drugs offered at the 25th percentile Part D formulary pricing: anastrozole, letrozole, and tamoxifen
91 ese results, IV minocycline was added to the formulary, primarily for the treatment of carbapenem-res
92 prescribing using such "top-down" methods as formulary restriction and prospective audit with feedbac
93                                     Hospital formulary restriction of clindamycin is an effective way
94 y and compatibility, and the local insurance formulary restriction to deliver an effective glaucoma m
95 g based on local susceptibility patterns and formulary restriction, and avoiding drugs with more prop
96 timicrobials, therapeutic substitutions, and formulary restriction.
97 onsideration, medical insurance coverage, or formulary restriction.
98                          Because the current formulary restrictions appear to be unlikely to change q
99  SUP based on prescribing patterns, hospital formulary restrictions, and cost-analysis should be cons
100 r understand the association between use and formulary restrictiveness.
101 5, 27%), guideline development (33, 6%), and formulary selection (8, 1%) appearing less often.
102 healthcare education, guideline development, formulary selection, and clinical care.
103 Professional (USP-DI), and American Hospital Formulary Service Drug Information (AHFS-DI), to identif
104                                     Personal formulary size and drugs used, physician and patient cha
105                  Institution median personal formulary size ranged from 150 (interquartile range, 82.
106                                     Personal formulary size was defined as the number of unique, newl
107          In multivariable modeling, personal formulary size was significantly associated with panel s
108                          Cost, institutional formulary status, and availability may restrict reversal
109 ake and usage patterns would inform hospital formularies, stewardship, and antibiotic development.
110 is cross-sectional study of Medicaid and ACA formularies, there was substantial variation in utilizat
111 vs co-payments) for medications in different formulary tiers.
112 igher-priced generic drugs on insurers' drug formularies to profit by creating a large difference bet
113                 The study found that the VHA formulary transition from budesonide-formoterol metered-
114       However, they were broadly accessible (formulary, unrestricted, tier 1 or 2) to only 14.4% and
115                                              Formularies varied substantially; however, all but 1 tre
116  covered for their Medicare patients because formularies vary widely among Medicare Part D plans and
117   Specific information about an individual's formulary was not available, so the authors could not es
118 dicare relies on private plans with distinct formularies, whereas the VA administers its own benefit
119 d 2,230 Medicare Advantage prescription drug formularies, which represent all formularies in 2014.
120 er 35% from a public healthcare insurer drug formulary while maintaining or improving patient care.

 
Page Top